Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy

Inclusion Criteria: * 1\. Age \> 18 years * 2\. Diagnosis of ATTR cardiac amyloidosis (wild-type or V142I ATTR mutation) a. Diagnosis of ATTR cardiac amyloidosis by established consensus diagnostic criteria of Gillmore et al. (either invasive or non-invasive diagnostic pathways) * 3\. Plan for initiation of tafamidis therapy for clinical indications and agree to continue tafamidis during the duration of the study. * 4\. Stated willingness to comply with all study procedures and availability for the duration of the study * 5\. Able to understand and sign the informed consent document after the nature of the study has been fully explained. * 6\. Women of childbearing potential who are sexually active with a non-sterilized male partner and males who are sexually active with a partner of childbearing potential must agree to use adequate contraception from screening until 30 days after the Flutemetamol. Exclusion Criteria: * 1\. Primary amyloidosis (AL) or secondary amyloidosis (AA). * 2\. Prior liver or heart transplantation. * 3\. Active malignancy or non-amyloid disease with an expected survival of less than 1 year * 4\. Inability to lie flat for 60 minutes in the PET scanner * 5\. History of prior treatment for ATTR cardiomyopathy and/or amyloid neuropathy, or decline clinical tafamidis treatment. * 6\. Pregnancy or lactation * 7\. Known allergic reactions to components of the 18F-flutemetamol and/or polysorbate 80 * 8\. High risk for non-adherence as determined by scree…